Pinealon Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Pinealon?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Neuroprotection, oxidative stress reduction, cognitive aging, circadian rhythm regulation, cardiovascular protection, dermal cell biology
• First Isolated: 1990s, St. Petersburg Institute of Bioregulation and Gerontology
• Molecular Weight: 418.41 g/mol
• Research Status: Preclinical models predominate; one published human study involving 32 subjects
• Key Mechanisms: Direct DNA interaction at CAG-containing promoter regions, reactive oxygen species suppression, ERK1/2 pathway modulation, caspase-3 regulation
• Published Studies: Majority from a single Russian research institution spanning three decades
• Clinical Trial Status: No peer-reviewed Phase I, II, or III trials registered in major international databases
• Regulatory Classification: Research use only; not approved for human therapeutic applications in any major jurisdiction

What is Pinealon?

Pinealon is a synthetic tripeptide composed of three amino acids arranged in the sequence glutamic acid, aspartic acid, and arginine, abbreviated as Glu-Asp-Arg or EDR. It weighs 418.41 g/mol and carries the CAS number 175175-23-2. Despite its simple three-amino-acid structure, Pinealon has attracted sustained scientific interest for a mechanistic profile unlike most research peptides: rather than binding to receptors on cell surfaces, its small size appears to allow it to traverse lipid membranes and enter the cell nucleus, where researchers propose it interacts directly with DNA.

The peptide was isolated and synthesized in the 1990s by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It was derived from Cortexin, a polypeptide neuroprotective complex extracted from the cerebral cortex of young animals, which had been used in Russian clinical medicine as a neuroprotective agent. The isolation of Pinealon represented an effort to identify and characterize specific active components within that broader complex. The name Pinealon reflects the compound’s investigated connections to pineal gland function and circadian biology, though the peptide itself is fully synthetic.

Research on Pinealon has continued for over three decades, producing a body of preclinical evidence across neurological, cardiovascular, and dermatological research areas. Studies have investigated the peptide in models of oxidative stress, prenatal hyperhomocysteinemia, ischemic injury, diabetic neuropathy, and age-related cognitive decline. The majority of this work originates from a single research institution, which introduces important considerations about independent replication. The most substantive human data consists of one published study involving 32 elderly subjects, leaving the translation from animal to human biology largely unconfirmed.

Pinealon belongs to a broader class of compounds called peptide bioregulators, short peptides studied for their proposed ability to modulate gene expression and exert tissue-specific biological effects. Within this class, its three-amino-acid structure places it among the smallest compounds studied, a size that researchers argue is central to its proposed nuclear penetration mechanism.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Pinealon contains two acidic amino acid residues, glutamic acid and aspartic acid, alongside one basic residue, arginine. This arrangement creates a specific charge profile: two negatively charged side chains paired with one positively charged side chain. Researchers hypothesize that this electrostatic configuration enables interactions with negatively charged nucleic acids and chromatin structures inside the cell nucleus.

The peptide’s three-amino-acid length is considered a functional feature rather than a structural limitation. Larger peptides cannot achieve the same degree of membrane penetration, making Pinealon’s small molecular footprint central to its proposed mechanism. Studies using HeLa cell models have demonstrated that the peptide penetrates both cellular and nuclear membranes, a finding that distinguishes it from most peptide research compounds that rely on surface receptor binding [1,2].

The sequence arrangement, Glu-Asp-Arg, distinguishes Pinealon from other short peptide bioregulators studied by the same research group. Related compounds with different amino acid sequences show distinct tissue targeting and biological activity profiles, suggesting that the specific charge arrangement in EDR, not merely peptide size, determines the interaction pattern with genomic material.

Mechanisms of Action Being Investigated

Pinealon’s proposed mechanisms span genomic, metabolic, and signaling pathways. The central hypothesis positions direct DNA interaction as the upstream event that triggers downstream effects across multiple biological systems.

Direct DNA Interaction and Gene Expression Modulation

Pinealon’s primary proposed mechanism involves crossing lipid bilayers, penetrating the nuclear envelope, and interacting directly with chromosomal DNA. Studies using HeLa cell models demonstrated nuclear membrane penetration and identified binding to CAG-containing promoter regions, where the peptide is thought to modulate transcriptional activity [2]. This is classified as an epigenetic mechanism: altering gene expression without changing the underlying DNA sequence.

Gene targets identified or proposed include those governing neuronal activity, neurotransmitter synthesis, cellular stress responses, protein synthesis, and cell survival signaling. Among the most studied is 5-tryptophan hydroxylase, the rate-limiting enzyme for serotonin synthesis, which Pinealon appears to upregulate through direct promoter interaction [1]. PPAR-alpha and PPAR-gamma have also been identified as binding targets, with regulatory effects that may reduce amyloid beta plaque formation in models relevant to Alzheimer’s disease research [3].

The complete cascade of gene expression changes produced by Pinealon has not been comprehensively mapped. Specific DNA binding sites have not been definitively characterized at the molecular level, and whether observed effects result directly from DNA binding or from secondary signaling cascades remains an open question in the literature.

Reactive Oxygen Species Suppression

Pinealon shows dose-dependent restriction of reactive oxygen species accumulation across multiple cell types, including cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells. Studies report decreased necrotic cell death as measured by propidium iodide assays and protection against hydrogen peroxide-induced cellular damage [4]. Antioxidant enzyme systems activated include NRF2, glutathione, and superoxide dismutase pathways.

A concentration-dependent relationship has been documented: ROS restriction occurs at lower peptide concentrations, while genomic and cell cycle effects manifest at higher concentrations. This tiered dose-response pattern suggests the peptide operates through at least two distinct mechanisms depending on local concentration. At lower doses, the antioxidant effect may dominate. At higher doses, genomic regulation becomes the predominant mode of action [4].

ERK1/2 Pathway Modulation

Pinealon suppresses activation of extracellular signal-regulated kinases ERK 1 and ERK 2 in neuronal cells exposed to homocysteine and other stressors. Documented effects include delayed ERK 1/2 phosphorylation under stress conditions, reduced activation of downstream stress-response cascades, and protection against excitotoxic neuronal damage [4]. ERK pathway regulation appears central to neuroprotective effects in hypoxic and ischemic conditions.

A note on literature framing: primary source studies describe ERK suppression under stress conditions, while some secondary sources frame MAPK/ERK activation as a beneficial effect of the peptide. These descriptions are not necessarily contradictory, as ERK modulation under pathological stress differs from baseline pathway activity, but the distinction merits attention when evaluating the evidence.

Caspase-3 Regulation and Apoptosis Modulation

Caspase-3 executes programmed cell death. Pinealon modulates its activity across neurons, cardiac tissue, and dermal cells. Ischemic stroke models show reduction of caspase-3 activation in neurons under hypoxic stress, with decreased apoptotic death across multiple tissue types [5,6]. Proapoptotic protein p53 modulation has also been noted in secondary research sources. Animal studies comparing Pinealon directly to Cortexin, its parent complex, reported superior maze navigation performance associated with caspase-3 modulation, suggesting the isolated tripeptide may retain or concentrate relevant activity from the parent complex.

NMDA Receptor Protection and Excitotoxicity Limitation

Pinealon reduces excitotoxicity by limiting NMDA receptor over-activation during hypoxic stress. This pathway is relevant in ischemic stroke models, alcohol withdrawal-induced neurotoxicity, and general hypoxic conditions. Studies have examined Pinealon’s effects on NMDA receptor subunit gene expression in the hippocampus of diabetic rats, linking the peptide’s genomic mechanism to specific receptor regulation in metabolically compromised neural tissue [7].

Serotonin Pathway Enhancement and Neuroendocrine Effects

By upregulating 5-tryptophan hydroxylase through promoter interaction, Pinealon increases serotonin synthesis capacity. Aging rat studies report elevated serotonin in cortical neurons following Pinealon administration. The serotonin-melatonin biosynthesis pathway connects this finding to the peptide’s proposed circadian effects: serotonin serves as a precursor for melatonin production in the pineal gland, and Pinealon’s influence on 5-tryptophan hydroxylase may restore melatonin availability in conditions of circadian disruption [1,3].

Additional neuroendocrine effects proposed include HPA axis regulation and influence on pineal gland baseline function under circadian disruption, though primary evidence for these effects is less extensively documented than the serotonergic pathway findings.

Irisin and FNDC5 Gene Regulation

Pinealon may regulate expression of irisin, a peptide encoded by the FNDC5 gene that is associated with cellular protection during physical activity. Irisin promotes neural differentiation and proliferation in brain tissue and correlates with telomere length in adults. Pinealon-mediated irisin upregulation has been described as an exercise-mimicking effect, though this characterization comes primarily from secondary sources and warrants verification against primary study data [8].

Major Areas of Research

Pinealon research spans neurological, cardiovascular, dermatological, and circadian biology, with the central thread being protection against oxidative stress and age-related cellular decline.

Neuroprotection Studies

Neuroprotection is Pinealon’s most extensively studied application. Researchers have examined the peptide in prenatal hyperhomocysteinemia models, ischemic stroke models, diabetic neuropathy models, and general hypoxic stress conditions.

In the prenatal hyperhomocysteinemia rat model, Pinealon administered to pregnant animals at 10 mcg/kg daily for five days reduced reactive oxygen species accumulation in cerebellar neurons of offspring, decreased necrotic cell counts, and improved spatial navigation performance in Morris Water Maze testing [9]. Offspring from treated mothers showed shortened platform search times and enhanced spatial learning relative to controls.

Ischemic stroke models demonstrate caspase-3 reduction in hypoxic neurons and ERK pathway suppression during excitotoxic stress [5,6]. These findings position Pinealon as a candidate for research into acute neuroprotective interventions, though all data originates from animal models.

Key Research Highlights:

• Reduced ROS accumulation in cerebellar neurons of offspring from treated pregnant rats [9]
• Decreased necrotic cell populations under oxidative stress conditions [4]
• Improved spatial learning and navigation in behavioral animal models [9]
• Caspase-3 reduction in ischemic neuronal models [5]

Cognitive Aging Research

Age-related cognitive decline represents a major focus area, driven by the peptide’s proposed genomic mechanism and its origins in gerontological research. Studies have examined Pinealon in aged rat models, investigating effects on cortical neuron serotonin levels, hippocampal NMDA receptor expression, and behavioral performance on cognitive tasks.

The single published human study in this area involved 32 elderly subjects and examined cognitive function outcomes. While this study represents the most direct human evidence available, the sample size and absence of independent replication limit conclusions that can be drawn [10].

Key Research Highlights:

• Increased cortical neuron serotonin in aged rat models
• Behavioral performance improvements on cognitive tasks in animal studies
• One human study in 32 elderly subjects; results require independent replication [10]

Cardiovascular Protection Studies

Cardiovascular research examines Pinealon’s protective effects in myocardial infarction models, investigating caspase-3 modulation in cardiac tissue and the peptide’s potential to limit cell death following ischemic events. The same apoptosis-limiting mechanisms studied in neuronal tissue appear to operate in cardiac cells, suggesting a tissue-nonspecific protective mechanism [5].

Anti-inflammatory effects relevant to vascular biology have been investigated alongside the direct cardiac protection findings. The combination of oxidative stress reduction and apoptosis modulation positions the peptide as a candidate for cardiovascular stress models, though dedicated cardiovascular research remains less extensive than the neurological literature.

Key Research Highlights:

• Caspase-3 modulation demonstrated in cardiac tissue post-myocardial infarction models [5]
• Oxidative stress protection relevant to ischemia-reperfusion injury models
• Anti-inflammatory effects observed in cardiovascular-adjacent research

Circadian Rhythm and Sleep Biology

Pinealon’s name reflects proposed connections to pineal gland function and circadian biology. The peptide’s upregulation of 5-tryptophan hydroxylase links it mechanistically to serotonin-melatonin biosynthesis, the pathway through which the pineal gland produces the circadian hormone melatonin.

Studies have investigated melatonin restoration in conditions of circadian disruption and effects on behavioral patterns associated with sleep quality. HPA axis regulation has been proposed as an additional mechanism connecting Pinealon to sleep-stress biology. This research area relies more heavily on mechanistic inference from the serotonin pathway findings than on dedicated circadian outcome studies [1,3].

Key Research Highlights:

• 5-tryptophan hydroxylase upregulation with downstream serotonin-melatonin pathway implications [1]
• Proposed melatonin restoration in circadian disruption models
• Behavioral pattern regulation in animal studies related to sleep quality

Dermatological and Skin Cell Research

Dermal cell biology represents a newer application area. Studies have examined caspase-3 modulation in dermal and epidermal cells, alongside irisin regulation and its potential effects on skin cell proliferation. Pinealon’s general anti-apoptotic profile in epithelial tissue types has driven investigation into wound healing and cellular aging applications within skin biology [8,11].

Key Research Highlights:

• Caspase-3 modulation documented in dermal and epidermal cell models [11]
• Irisin regulation with potential skin cell proliferation implications [8]
• Anti-aging skin cell applications investigated through cellular aging lens

Alzheimer’s Disease and Neurodegeneration

The identification of PPAR-alpha and PPAR-gamma as Pinealon binding targets has opened investigation into Alzheimer’s disease-relevant mechanisms. PPAR receptor activation is associated with downregulation of amyloid beta plaque formation, the hallmark pathological feature of Alzheimer’s disease [3]. Restoration of dendritic spines in a Huntington’s disease animal model suggests the peptide may have broader neurodegeneration research applications beyond Alzheimer’s-specific pathology.

Key Research Highlights:

• PPAR-alpha and PPAR-gamma binding with amyloid beta regulation relevance [3]
• Dendritic spine restoration demonstrated in Huntington’s disease animal model
• Broader neurodegeneration research applications suggested by synaptic plasticity findings

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Pinealon’s pharmacokinetic profile has not been fully characterized in peer-reviewed literature. As a tripeptide, it is subject to rapid degradation by peptidases present in blood and tissues, which typically results in short plasma half-lives for compounds of this class. Its small molecular size and specific charge profile are proposed to facilitate membrane penetration, but the rate and extent of this penetration under physiological conditions have not been quantified in comprehensive pharmacokinetic studies.

Research protocols have employed both injectable and oral administration routes in animal studies. Oral bioavailability data is extremely limited. The three-amino-acid structure provides greater resistance to gastric and intestinal degradation than larger peptides, but measurable systemic bioavailability via oral administration has not been established with the rigor required to draw firm conclusions.

Distribution and Metabolism

The proposed nuclear penetration mechanism implies intracellular distribution following cellular uptake, a distribution pattern distinct from peptides that remain extracellular or membrane-bound. Cell culture studies using HeLa cells have demonstrated nuclear membrane penetration, establishing that intracellular distribution occurs in vitro [2]. Tissue distribution in living animals has not been mapped with radiolabeled compound studies published in peer-reviewed literature.

Metabolic breakdown follows standard tripeptide degradation pathways through peptidase activity in plasma and tissues. The products are the three constituent amino acids, which are either recycled into protein synthesis or further metabolized through standard amino acid pathways. No unusual or toxic metabolites have been identified.

Delivery Methods Under Investigation

• Subcutaneous injection: The most common delivery method in animal research studies; provides direct systemic availability without first-pass hepatic metabolism
• Intraperitoneal injection: Used extensively in rodent research models; enables rapid systemic distribution in experimental settings
• Oral administration: Investigated in some protocols; bioavailability data remains limited and the oral route has not been validated against injectable routes in controlled comparative studies
• Intranasal administration: Proposed as a route for central nervous system delivery, bypassing the blood-brain barrier; limited direct research published

Excretion and Clearance

Clearance of Pinealon and its amino acid metabolites follows standard renal and hepatic elimination pathways. No specific excretion studies targeting Pinealon have been published. Plasma half-life is estimated as short based on tripeptide pharmacology generally, though this estimate has not been confirmed with direct pharmacokinetic measurement in published studies.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data The most significant gap in the Pinealon evidence base is the near-complete absence of human clinical data. One published study involving 32 elderly subjects represents the entirety of human evidence. No Phase I safety trials, Phase II efficacy trials, or Phase III confirmatory trials have been registered or published in major international databases. The safety profile in humans is essentially unknown, and all dosing parameters used in animal research cannot be extrapolated to human application without dedicated human pharmacokinetic studies.

Institutional Concentration The overwhelming majority of published Pinealon research originates from a single institution, the St. Petersburg Institute of Bioregulation and Gerontology, under a single primary investigator group. Independent replication by separate research teams at unaffiliated institutions is largely absent. This concentration of research origin is a fundamental limitation on the evidence base regardless of the quality of individual studies, as independent replication is the standard mechanism for validating preclinical findings.

Mechanistic Gaps The DNA interaction mechanism, while supported by cell culture evidence, has not been characterized at the level of specific binding site identification or comprehensive gene expression mapping. Whether biological effects result directly from DNA binding or from secondary signaling pathways remains incompletely resolved. The distinction between ERK suppression under stress conditions and MAPK/ERK pathway activation described in secondary sources has not been reconciled in primary literature.

Methodological Considerations Animal studies use varying doses, administration routes, and model systems, making cross-study comparisons difficult. Most pharmacokinetic parameters remain undefined. Long-term effects beyond typical study durations have not been examined. Potential interactions with medications or other compounds are unstudied.

Areas Needing Further Investigation

• Human pharmacokinetic and safety characterization: the foundational prerequisite for any clinical application
• Independent replication by research groups unaffiliated with the originating institution
• Comprehensive gene expression mapping to characterize the downstream effects of DNA promoter interaction
• Direct comparison studies between Pinealon and clinically established neuroprotective agents
• Long-term safety assessment in chronic administration models
• Oral bioavailability validation and comparison with injectable routes

Regulatory and Research Status

Current Classification

FDA Status Pinealon is not approved by the FDA for any human therapeutic use. It is classified as an unapproved new drug in the United States and is available only for legitimate laboratory research purposes. No investigational new drug application has been filed or approved for Pinealon in the United States based on publicly available regulatory records.

WADA Status Pinealon does not currently appear on the WADA prohibited list as a specifically named compound. However, its classification as a peptide bioregulator may place it within broader peptide categories covered by WADA regulations. Researchers and athletes subject to anti-doping oversight should verify current WADA guidance before any involvement with this compound.

International Perspective Pinealon has been used in Russian research medicine as part of the broader Khavinson peptide bioregulator program, and products in this category have been marketed in Russia and some Eastern European markets under different regulatory frameworks than those applied in the United States and European Union. In the EU, Pinealon is not approved by the EMA for human therapeutic use. Most major international regulatory bodies classify it as a research chemical requiring institutional oversight for legitimate use.

Research Community Approach

Active preclinical research continues primarily at Russian academic institutions. The compound has attracted limited pharmaceutical industry investment in Western markets, reflecting the early-stage evidence base and the absence of established IP protection pathways for naturally-derived short peptides. Legitimate research requires appropriate biosafety protocols, institutional review, and compliance with applicable research regulations in the jurisdiction where work is conducted.

Future Research Directions

The most critical need is independent replication of existing findings by research groups outside the originating institution. Human pharmacokinetic studies to establish basic safety and distribution parameters represent the necessary next step toward any clinical development pathway. The compound’s distinctive proposed mechanism, direct DNA interaction, remains scientifically intriguing and warrants investigation using modern genomic tools that were not available during the initial research period.

Key Research Findings

Prenatal Neuroprotection Study

Research Focus: Effects of maternal Pinealon administration on offspring neuroprotection in a rat model of prenatal hyperhomocysteinemia Key Results: Reduced ROS accumulation in cerebellar granule neurons of offspring; decreased necrotic cell populations; improved spatial learning performance in Morris Water Maze testing; shortened platform search times relative to untreated controls Significance: Demonstrates that maternal peptide administration can influence offspring neurological development in animal models; establishes oxidative stress protection as a measurable outcome in a developmentally relevant model Limitations: Rat model; prenatal administration protocol; no human data; single research institution [9]

Oxidative Stress Dose-Response Study

Research Focus: Dose-dependent ROS restriction and cell cycle effects across multiple cell types including cerebellar granule cells, neutrophils, and PC12 cells Key Results: Dose-dependent ROS reduction confirmed; decreased necrotic cell death by propidium iodide assay; protection against hydrogen peroxide-induced damage; lower concentrations produced antioxidant effects while higher concentrations produced genomic and cell cycle effects; suppression of both receptor-dependent and receptor-independent ROS sources Significance: Establishes the tiered, concentration-dependent mechanism that distinguishes Pinealon’s profile from single-pathway antioxidants; provides mechanistic framework for understanding the peptide’s broad reported effects Limitations: Cell culture and animal models; concentration-activity relationship not validated in human tissue; specific genomic targets not mapped [4]

Ischemic Injury and Caspase-3 Study

Research Focus: Caspase-3 modulation in neurons and cardiac tissue under hypoxic and ischemic stress conditions Key Results: Reduced caspase-3 activation in neurons exposed to hypoxic stress; decreased apoptotic cell death in cardiac tissue from myocardial infarction models; protective effects observed across tissue types suggesting a generalized anti-apoptotic mechanism Significance: Positions Pinealon as a candidate for research into acute injury protection across multiple organ systems; cross-tissue relevance strengthens the mechanistic case for a genomic-level rather than tissue-specific mechanism Limitations: Animal models only; cardiac and neuronal human data absent; optimal protective dosing undefined [5,6]

NMDA Receptor and Hippocampal Gene Expression Study

Research Focus: Effects of Pinealon on NMDA receptor subunit gene expression in the hippocampus of diabetic rats Key Results: Modulation of NMDA receptor subunit gene expression in hippocampal tissue; connection established between metabolic disease context and Pinealon’s gene regulatory activity; excitotoxicity limitation in conditions of metabolic compromise Significance: Extends the research application to metabolic disease-associated neurological complications; demonstrates that the DNA interaction mechanism produces measurable gene expression changes in a specific, clinically relevant brain region Limitations: Diabetic rat model; hippocampal gene expression changes not mapped comprehensively; human diabetic neuropathy application entirely untested [7]

Human Elderly Subject Study

Research Focus: Cognitive and neurological outcomes in elderly human subjects Key Results: Cognitive function outcomes examined in 32 elderly subjects; specific outcome measures and effect sizes reported in the published study Significance: Represents the only published human clinical data for Pinealon; establishes that human research has been conducted and provides a baseline for future studies Limitations: 32 subjects is insufficient for conclusions about efficacy or safety; no independent replication; absence of peer-reviewed Phase I/II/III trial structure; study originated from the same research institution as all other Pinealon publications [10]

DNA Penetration and Nuclear Interaction Study

Research Focus: Characterization of Pinealon’s ability to penetrate cellular and nuclear membranes in HeLa cell models Key Results: Demonstrated penetration of both cellular and nuclear membranes; identified interaction with CAG-containing promoter regions; established the mechanistic basis for epigenetic gene expression modulation Significance: Provides the primary experimental evidence for the distinctive mechanistic hypothesis that defines Pinealon research; without this mechanistic foundation, the broad range of reported biological effects would lack a unifying explanation Limitations: HeLa cells are a human cervical cancer cell line; findings in cancerous cell models require careful interpretation when extrapolating to normal physiology; specific binding site mapping incomplete [2]

Frequently Asked Questions

What is Pinealon?

Pinealon is a synthetic research tripeptide made from three amino acids: glutamic acid, aspartic acid, and arginine. It was originally isolated from a neuroprotective brain extract called Cortexin in the 1990s and has since been studied independently for its proposed ability to enter cell nuclei and influence gene expression. All research on Pinealon is conducted in laboratory settings and it is not approved for human use.

What makes Pinealon different from other research peptides?

Most peptides work by binding to receptors on the surface of cells, similar to how a key fits a lock. Pinealon is studied because its extremely small three-amino-acid size appears to allow it to pass through cell membranes and enter the nucleus, where DNA is stored. Researchers hypothesize this direct DNA interaction, rather than surface receptor binding, explains the wide range of biological effects observed in preclinical studies.

How long has Pinealon been studied?

Research on Pinealon has spanned more than three decades, beginning with its isolation in the 1990s at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. The majority of that research comes from the same institution and research group, which means independent replication by other labs remains limited despite the length of the research timeline.

Is Pinealon the same as a pineal gland supplement?

No. Although the name Pinealon reflects the peptide’s investigated connections to pineal gland function and circadian rhythm biology, Pinealon itself is a fully synthetic compound. It is not derived from pineal gland tissue and is not equivalent to melatonin or other pineal gland-related compounds. Researchers study Pinealon partly because it appears to influence the serotonin-melatonin biosynthesis pathway, but the compound’s identity and mechanism are distinct from glandular supplements.

What is the current state of human research on Pinealon?

Human research on Pinealon is extremely limited. One published study examined 32 elderly subjects, and no Phase I, II, or III clinical trials have been registered or published in major international databases. This means the safety, dosing, and effectiveness of Pinealon in humans remain unknown from a clinical evidence standpoint. All current knowledge about Pinealon’s biological effects comes primarily from animal and cell culture studies.

References

1. Khavinson, V.K., & Malinin, V.V. (2005). Gerontological Aspects of Genome Peptide Regulation. Karger AG.

2. Fedoreyeva, L.I., Kireev, I.I., Khavinson, V.K., & Vanyushin, B.F. (2013). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro binding of the peptides to deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 78(6), 675-682. PubMed

3. Khavinson, V.K., Linkova, N.S., Kvetnoy, I.M., Kvetnaia, T.V., & Polyakova, V.O. (2012). Pinealon affects morphofunctional state of the pineal gland under conditions of circadian rhythm disorder. Bulletin of Experimental Biology and Medicine, 153(4), 564-567. PubMed

4. Khavinson, V.K., Shataeva, L.K., & Linkova, N.S. (2011). Cell cycle regulation by short peptides. Rejuvenation Research, 14(3), 313-321. PubMed

5. Mendzheritskii, A.M., Karantysh, G.V., Ryzhak, G.A., & Kovaleva, Z.V. (2015). Effect of peptide EDR on oxidative stress markers and brain-specific proteins in rats with experimental cerebral ischemia. Advances in Gerontology, 5(2), 83-87.

6. Kozina, L.S., Arutjunyan, A.V., & Khavinson, V.K. (2008). Antioxidant properties of geroprotective peptides of the pineal gland. Doklady Biological Sciences, 418(1), 7-10. PubMed

7. Karantysh, G.V., Mendzheritskiy, A.M., Ryzhak, G.A., & Kovaleva, Z.V. (2020). Molecular mechanisms of protective effects of Glu-Asp-Arg peptide on hippocampal NMDA receptor expression in diabetic rats. Neurochemical Journal, 14(1), 61-67.

8. Khavinson, V.K., Linkova, N.S., Diatlova, A.S., & Trofimova, S.V. (2020). Peptide regulation of differentiation of multipotent stromal cells. Advances in Gerontology, 10(3), 194-201.

9. Arutjunyan, A., Kozina, L., Stvolinskiy, S., Bulygina, Y., Mashkina, A., & Khavinson, V. (2012). Pinealon protects the rat offspring against prenatal hyperhomocysteinemia. International Journal of Clinical and Experimental Medicine, 5(2), 179-185. PubMed

10. Khavinson, V.K., Popovich, I.G., Linkova, N.S., Myl’nikov, S.V., & Oparina, T.I. (2012). Biological activity of tetrapeptide Epitalon and tripeptide Pinealon in elderly subjects. Gerontology and Geriatrics, 19, 114-119.

11. Khavinson, V.K., Linkova, N.S., Kozhevnikova, E., Dyatlova, A., & Kvetnoy, I. (2020). EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of skin aging. International Journal of Molecular Sciences, 21(2), 561. PubMed

12. Karantysh, G.V., & Mendzheritskii, A.M. (2012). Effect of peptide Pinealon on morphological characteristics of brain cortex of rats after acute hypobaric hypoxia. Advances in Gerontology, 2(1), 27-33.

13. Khavinson, V.K., Linkova, N.S., Polyakova, V.O., Kvetnoy, I.M., & Myl’nikov, S.V. (2013). Mechanism of neuroprotective effects of tripeptide EDR in aging. Advances in Gerontology, 3(3), 243-246.

14. Linkova, N.S., Khavinson, V.K., Diatlova, A.S., & Rubtsov, V.Yu. (2016). Peptide regulation of the expression of genes encoded in growth factor receptors in old age-related pathological conditions. Bulletin of Experimental Biology and Medicine, 161(3), 405-409. PubMed

15. Khavinson, V., Linkova, N., Dyatlova, A., Kantemirova, R., & Kozlov, K. (2021). Senescence-associated secretory phenotype of endothelial cells and peptide regulation of aging. Biomedicines, 9(10), 1302. PubMed